KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Other financing activities (2016 - 2025)

Historic Other financing activities for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$1.3 million.

  • Biogen's Other financing activities fell 12954.55% to -$1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 million, marking a year-over-year increase of 32727.27%. This contributed to the annual value of $5.0 million for FY2025, which is 32727.27% up from last year.
  • Latest data reveals that Biogen reported Other financing activities of -$1.3 million as of Q4 2025, which was down 12954.55% from $6.2 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Other financing activities registered a high of $16.5 million during Q1 2023, and its lowest value of -$106.2 million during Q2 2021.
  • Its 5-year average for Other financing activities is -$3.5 million, with a median of $1.3 million in 2025.
  • Per our database at Business Quant, Biogen's Other financing activities plummeted by 83241.38% in 2021 and then soared by 395000.0% in 2023.
  • Biogen's Other financing activities (Quarter) stood at $400000.0 in 2021, then plummeted by 50.0% to $200000.0 in 2022, then soared by 3950.0% to $8.1 million in 2023, then plummeted by 45.68% to $4.4 million in 2024, then crashed by 129.55% to -$1.3 million in 2025.
  • Its Other financing activities stands at -$1.3 million for Q4 2025, versus $6.2 million for Q3 2025 and -$1.2 million for Q2 2025.